Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

Core Points - Protagenic Therapeutics has been granted a new patent in Japan for its modified stilbenoid program, which is crucial for its pipeline asset aimed at treating epilepsy and seizures, with the patent valid until March 31, 2041 [3][4] - The company previously secured a similar patent in the UK, indicating its ongoing innovation and commitment to protecting its development pipeline [4] - The Japanese pharmaceutical market is the third-largest globally, valued at over $85 billion in 2025, projected to reach $93 billion by 2030 [4] - The global epilepsy drug market is expected to grow from $11.29 billion in 2024 to approximately $18.74 billion by 2034, with a compound annual growth rate (CAGR) of 5.20% from 2025 to 2034 [5]